ProMIS Neurosciences Announces July 28 Webinar To Discuss Six-Month Blinded Interim Data From PMN310 PRECISE-AD Phase 1b Trial In Early Alzheimer's

Loading news article.

ProMIS Neurosciences Announces July 28 Webinar To Discuss Six-Month Blinded Interim Data From PMN310 PRECISE-AD Phase 1b Trial In Early Alzheimer's | WAPE

ProMIS Neurosciences Announces July 28 Webinar To Discuss Six-Month Blinded Interim Data From PMN310 PRECISE-AD Phase 1b Trial In Early Alzheimer's

Article summary

Related companies

Comments —